NCT06162377 2025-12-17Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.M.D. Anderson Cancer CenterPhase 4 Recruiting25 enrolled
NCT00858754 2019-11-29Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer SubjectsBausch Health Americas, Inc.Phase 4 Withdrawn